Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.

Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.

Dual-targeted therapy is effective and safe for difficult-to-treat inflammatory bowel disease.

Targeting androgen receptor signaling may improve acute myeloid leukemia treatment.

Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.

Budesonide and N-acetylcysteine reduced tumors and alopecia in mice, regardless of FHIT gene status.

Sorafenib causes skin reactions by increasing the number and activity of skin mast cells.

CS12192 effectively treats alopecia areata with better safety than current options.

JAK1 inhibitor may effectively treat alopecia areata when TNF-α inhibitors and corticosteroids fail.

Aminopterin effectively improves skin conditions but has toxic side effects that need careful monitoring.

Finasteride may reduce prostate tumor cell invasion and spread.

Tofacitinib may effectively treat folliculitis decalvans.

Peficitinib can turn human fibroblasts into cells that help grow hair.

Baricitinib 4 mg is effective and safe for treating severe alopecia areata.

Eclipta alba extract may work as an anticancer agent and help reverse drug resistance.

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.

Six African American women experienced hair loss after switching to a new HIV medication.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.

Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.

Selumetinib causes skin and hair side effects in kids with NF1, affecting treatment and quality of life.

Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Targeting specific metabolic and ionic pathways may improve alopecia areata treatment.

No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.

Upadacitinib effectively treats skin conditions like eczema and psoriasis and is becoming more widely used and affordable.

Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.

Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.

Plerixafor may help treat pigmentation disorders by promoting skin repigmentation.